Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Equity: 2020-2025

Historic Return on Equity for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Sep 2025 value amounting to 15.14%.

  • Insight Molecular Diagnostics' Return on Equity rose 1782.00% to 15.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.14%, marking a year-over-year increase of 1782.00%. This contributed to the annual value of -14.90% for FY2024, which is 1479.00% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Return on Equity stood at 15.14% for Q3 2025, which was up 234.33% from -11.27% recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Return on Equity high stood at 56.98% for Q1 2025, and its period low was -11.27% during Q2 2025.
  • For the 3-year period, Insight Molecular Diagnostics' Return on Equity averaged around 10.96%, with its median value being -1.25% (2023).
  • Over the last 5 years, Insight Molecular Diagnostics' Return on Equity had its largest YoY gain of 5,948bps in 2025, and its largest YoY loss of 915bps in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Return on Equity (Quarterly) stood at -0.82% in 2021, then dropped by 22bps to -1.04% in 2022, then declined by 13bps to -1.17% in 2023, then skyrocketed by 4,869bps to 47.52% in 2024, then skyrocketed by 1,782bps to 15.14% in 2025.
  • Its last three reported values are 15.14% in Q3 2025, -11.27% for Q2 2025, and 56.98% during Q1 2025.